Postdoctoral Fellow, Tumor Microenvironment of Gastrointestinal; GI Cancers

Postdoctoral Fellow, Tumor Microenvironment of Gastrointestinal (GI) Cancers

New York, NY (Onsite)

Biohub is a 501(c)(3) biomedical research organization building the first large-scale scientific initiative combining frontier AI with frontier biology to solve disease. We build the technology to help scientists around the world use AI-powered biology to study how cells operate, organize, and work as part of systems to understand why disease happens and how to correct it. With our compute capacity, AI research and engineering, and state-of-the‑art technology for measuring, imaging, and programming biology, we are enabling scientists worldwide to use AI-powered biology to advance our understanding of human health.

Our immune cell reprogramming team integrates foundational research on immunology and disease biology with AI-modeling to develop engineered cells that harness our own immune system to detect and treat early signs of age‑related diseases, like cancer, Alzheimer’s, and Parkinson’s. These technologies will enable precise, context‑dependent therapeutic responses only when and where it is needed. Learn more about our work here.

Our work brings together three powerhouse universities – Columbia University, The Rockefeller University, and Yale University – into a single collaborative technology and discovery engine.

Our Vision

• Pursue large scientific challenges that cannot be pursued in conventional environments
• Enable individual investigators to pursue their riskiest and most innovative ideas
• Facilitate research by scientists and clinicians at our home institutions and beyond

We are a team of passionate individuals powered by technology, guided by scientific research, and driven by collaboration, working toward a mission to cure or prevent all disease.

The Laboratory of Immunogenomics at Biohub in NY () studies the non‑coding regulatory genome to understand and address immune dysfunction in diseases like cancer, autoimmune disorders, and aging. We focus on enhancers—non‑coding, highly cell‑type‑specific transcriptional regulatory elements—and their role in shaping immune responses.

We develop and utilize genomic technologies, including bulk and single‑cell nascent RNA sequencing, genome editing, immune engineering, and CRISPR‑based functional screens in patient biopsies, organoid systems, and mouse models. Through computational analysis integrating machine learning and AI, we map enhancer‑gene networks and identify disease‑driving elements. Our goal is to advance enhancer‑guided precision genomic medicine for diseases involving immune dysfunction.

We are seeking a Postdoctoral Fellow to lead research on the immune and stromal components of the tumor microenvironment (TME) in gastrointestinal cancers. The goal is to identify and characterize the cancer‑cell intrinsic and extrinsic regulatory mechanisms that influence pro‑inflammatory and anti‑inflammatory immune dynamics, with the aim of developing new therapeutic targets and improving existing treatments such as immune checkpoint inhibitors and combination therapies.

This role will involve in vivo studies using genetically engineered mouse models (GEMMs), syngeneic and patient‑derived xenograft (PDX) models, and human patient‑derived organoids. The project integrates immunology, cancer biology, stromal biology, and translational research in close collaboration with multidisciplinary teams.

• Profile immune cell populations in TME using flow cytometry, single‑cell RNA‑seq, and spatial transcriptomics.
• Assess immune cell function via cytokine/chemokine measurement, cytotoxicity assays, and antigen presentation studies.
• Characterize the balance between pro‑ and anti‑inflammatory cell populations during tumor progression and treatment.
• Characterize cancer‑associated fibroblast (CAF) subtypes and their impact on immune modulation and therapy resistance.
• Study extracellular matrix remodeling and fibrosis‑associated immunosuppression in tumors.
• Identify stromal targets that could enhance immune infiltration or therapy delivery.
• Maintain and use GEMMs, syngeneic, and PDX models of GI cancers.
• Conduct orthotopic and subcutaneous…